Abstract
Systemic lupus erythematosus is more than a heterogeneous autoimmune disease. It is in fact a syndrome of many different clinical genotypes and phenotypes. This review covers the most recently studied monoclonal antibodies and those currently being investigated. The key trials are summarized, including those for biologics on the market for two decades and those just approved for lupus less than two years ago. The focus will be on the following four: Rituximab, Abatacept, Belimumab, and Epratuzumab. It is a challenge to design the perfect trial and study patients with this disease as each has his or her own unique manifestations, biological markers, and underlying genetic background. However, as our understanding of the immune mechanisms involved in lupus increases; novel therapies will emerge that can be utilized for appropriately selected patients.
Keywords: Antibodies, biologics, lupus, monoclonal antibody, SLE, systemic lupus erythematosus, treatment.
Current Pharmaceutical Biotechnology
Title:Update on the Use of Biologics in Lupus
Volume: 15 Issue: 6
Author(s): Manisha Relan, Sahana Vishwanath, Long Shen and Julian L. Ambrus Jr
Affiliation:
Keywords: Antibodies, biologics, lupus, monoclonal antibody, SLE, systemic lupus erythematosus, treatment.
Abstract: Systemic lupus erythematosus is more than a heterogeneous autoimmune disease. It is in fact a syndrome of many different clinical genotypes and phenotypes. This review covers the most recently studied monoclonal antibodies and those currently being investigated. The key trials are summarized, including those for biologics on the market for two decades and those just approved for lupus less than two years ago. The focus will be on the following four: Rituximab, Abatacept, Belimumab, and Epratuzumab. It is a challenge to design the perfect trial and study patients with this disease as each has his or her own unique manifestations, biological markers, and underlying genetic background. However, as our understanding of the immune mechanisms involved in lupus increases; novel therapies will emerge that can be utilized for appropriately selected patients.
Export Options
About this article
Cite this article as:
Relan Manisha, Vishwanath Sahana, Shen Long and Jr L. Ambrus Julian, Update on the Use of Biologics in Lupus, Current Pharmaceutical Biotechnology 2014; 15 (6) . https://dx.doi.org/10.2174/1389201015666140804162053
DOI https://dx.doi.org/10.2174/1389201015666140804162053 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Triggering of Apoptosis and Pro-Inflammatory Cytokines in NK Cells: Regulation by Cyclosporin A
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Mesenchymal Stem Cell as a Potential Therapeutic for Inflammatory Bowel Disease- Myth or Reality?
Current Stem Cell Research & Therapy Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies
Current Rheumatology Reviews Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Myocardial Inflammation in Autoimmune Diseases: Investigation by Cardiovascular Magnetic Resonance and Endomyocardial Biopsy
Inflammation & Allergy - Drug Targets (Discontinued) Expression and Function of Cytokines and Chemokines in Neuropsychiatric Related Systemic Lupus Erythematosus
Current Rheumatology Reviews Human Fetal Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Genetic Susceptibility to Autoimmune Disorders: Clues from Gene Association and Gene Expression Studies
Current Molecular Medicine Implication of CD154/CD40 Interaction in Healthy and Autoimmune Responses
Current Immunology Reviews (Discontinued) Modulation of Hepatocyte Apoptosis: Cross-talk Between Bile Acids and Nuclear Steroid Receptors
Current Medicinal Chemistry Inhibitors of AP-1 and NF-κB Mediated Transcriptional Activation: Therapeutic Potential in Autoimmune Diseases and Structural Diversity
Current Medicinal Chemistry Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials Diagnosis of Inflammatory Bowel Disease by Abdominal Ultrasound and Color Doppler Techniques
Current Medical Imaging Paracoccidioides spp. and Histoplasma capsulatum: Current and New Perspectives for Diagnosis and Treatment
Current Topics in Medicinal Chemistry Diabetes Mellitus: A Potential Target for Stem Cell Therapy
Current Stem Cell Research & Therapy Application of Agents Against Interferon-Gamma-Dependent Chemokines in Immunotherapy
Letters in Drug Design & Discovery Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine Recent Developments in the Discovery of Selective Glucocorticoid Receptor Modulators (SGRMs)
Current Topics in Medicinal Chemistry Comparative Biochemistry of GH3, GH20 and GH84 β-N-acetyl-Dhexosaminidases and Recent Progress in Selective Inhibitor Discovery
Current Drug Targets